Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy

Seminars in Oncology

Volumn 26, Issue 5 SUPPL. 14, 1999, Pages 97-106

  Treon, S P ^a   Shima, Y ^a   Preffer, F I ^a   Doss, D S ^a   Ellman, L ^a   Schlossman, R L ^a   Grossbard, M L ^a   Belch, A R ^a   Pilarski, L M ^a   Anderson, K C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CHLORAMBUCIL; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GAMMA INTERFERON; MELPHALAN; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; MALE; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PLASMA CELL; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BIOLOGICAL RESPONSE MODIFIERS; CLINICAL TRIALS, PHASE II; FLOW CYTOMETRY; HUMANS; IMMUNIZATION, PASSIVE; INTERFERON TYPE II; MALE; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PHENOTYPE; WALDENSTROM MACROGLOBULINEMIA;

EID: 0032739712     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)